RU2353364C2 - Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов - Google Patents
Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов Download PDFInfo
- Publication number
- RU2353364C2 RU2353364C2 RU2005112711/14A RU2005112711A RU2353364C2 RU 2353364 C2 RU2353364 C2 RU 2353364C2 RU 2005112711/14 A RU2005112711/14 A RU 2005112711/14A RU 2005112711 A RU2005112711 A RU 2005112711A RU 2353364 C2 RU2353364 C2 RU 2353364C2
- Authority
- RU
- Russia
- Prior art keywords
- mds
- vitamin
- ptk787
- combination
- pyridylmethylphthalazine
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title claims abstract description 42
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 title abstract description 21
- 238000002360 preparation method Methods 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 229950000578 vatalanib Drugs 0.000 claims abstract description 13
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102000003951 Erythropoietin Human genes 0.000 claims description 6
- 108090000394 Erythropoietin Proteins 0.000 claims description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229940105423 erythropoietin Drugs 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 5
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- -1 PTK787 4-pyridylmethylphthalazine derivative Chemical class 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000011443 conventional therapy Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 238000011254 conventional chemotherapy Methods 0.000 abstract description 3
- 230000001934 delay Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 208000031162 sideroblastic anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| US60/413,176 | 2002-09-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005112711A RU2005112711A (ru) | 2006-02-27 |
| RU2353364C2 true RU2353364C2 (ru) | 2009-04-27 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005112711/14A RU2353364C2 (ru) | 2002-09-24 | 2003-09-23 | Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (enExample) |
| EP (1) | EP1545534B1 (enExample) |
| JP (1) | JP2006502195A (enExample) |
| KR (1) | KR20050074450A (enExample) |
| CN (1) | CN100372535C (enExample) |
| AT (1) | ATE359789T1 (enExample) |
| AU (1) | AU2003299065B2 (enExample) |
| BR (1) | BR0314647A (enExample) |
| CA (1) | CA2499738A1 (enExample) |
| CR (1) | CR7754A (enExample) |
| DE (1) | DE60313344T2 (enExample) |
| EC (1) | ECSP055700A (enExample) |
| ES (1) | ES2285251T3 (enExample) |
| HR (1) | HRP20050281A2 (enExample) |
| MX (1) | MXPA05003161A (enExample) |
| NO (1) | NO20051936L (enExample) |
| PL (1) | PL374696A1 (enExample) |
| PT (1) | PT1545534E (enExample) |
| RS (1) | RS20050228A (enExample) |
| RU (1) | RU2353364C2 (enExample) |
| WO (1) | WO2004028542A1 (enExample) |
| ZA (1) | ZA200502212B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407683T1 (de) * | 1997-10-15 | 2008-09-15 | Polarx Biopharmaceuticals Inc | Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| RU2168995C2 (ru) * | 1994-09-06 | 2001-06-20 | Йель Юниверсити | Фармацевтические композиции, соединения, способы получения соединений |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CA2366857C (en) * | 1999-03-30 | 2010-12-14 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| CA2393252A1 (en) * | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
-
2003
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2168995C2 (ru) * | 1994-09-06 | 2001-06-20 | Йель Юниверсити | Фармацевтические композиции, соединения, способы получения соединений |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
Non-Patent Citations (1)
| Title |
|---|
| WOOD J.M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial grouth factor-induced responses and tumor growth after oral administration. Cancer res, 2000 Apr 15; 60(8): 2178-89. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003299065B2 (en) | 2006-10-26 |
| JP2006502195A (ja) | 2006-01-19 |
| US20060128716A1 (en) | 2006-06-15 |
| ATE359789T1 (de) | 2007-05-15 |
| ECSP055700A (es) | 2005-08-11 |
| CN1684684A (zh) | 2005-10-19 |
| NO20051936L (no) | 2005-06-23 |
| RU2005112711A (ru) | 2006-02-27 |
| CR7754A (es) | 2005-12-02 |
| DE60313344D1 (de) | 2007-05-31 |
| PL374696A1 (en) | 2005-10-31 |
| WO2004028542A1 (en) | 2004-04-08 |
| ZA200502212B (en) | 2006-02-22 |
| CN100372535C (zh) | 2008-03-05 |
| ES2285251T3 (es) | 2007-11-16 |
| DE60313344T2 (de) | 2008-01-03 |
| CA2499738A1 (en) | 2004-04-08 |
| HRP20050281A2 (en) | 2006-07-31 |
| BR0314647A (pt) | 2005-08-02 |
| EP1545534A1 (en) | 2005-06-29 |
| MXPA05003161A (es) | 2005-09-12 |
| EP1545534B1 (en) | 2007-04-18 |
| KR20050074450A (ko) | 2005-07-18 |
| RS20050228A (sr) | 2007-08-03 |
| AU2003299065A1 (en) | 2004-04-19 |
| PT1545534E (pt) | 2007-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1339458B1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| KR20230148208A (ko) | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 | |
| US20110281814A1 (en) | Methods and compositions for treating breast cancer | |
| RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| US20060111358A1 (en) | Treatment of aml | |
| RU2353364C2 (ru) | Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов | |
| US20090233973A1 (en) | Epothilone derivatives for the treatment of multiple myeloma | |
| US20080090848A1 (en) | Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides | |
| US12472227B2 (en) | Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy | |
| EP1441717B1 (en) | Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog | |
| US20090233939A1 (en) | Treatment of amm | |
| EP3854411A1 (en) | Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy | |
| AU2024238523A1 (en) | Pharmaceutical composition and use thereof | |
| WO2023118062A1 (en) | Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers | |
| WO2008118164A1 (en) | Compounds to promote regeneration of bone marrow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100924 |